Immutep

Immutep is listed on the Australian Stock Exchange (ASX:IMM) and on the NASDAQ Global Market (NASDAQ:IMMP) in the U.S. (ADR's).  

We are a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, with operations in Europe, Australia, and the U.S.

We are the global leader in the understanding of and in the development of therapeutics that modulate Lymphocyte Activation Gene-3 (“LAG-3”), a cell surface molecule which plays a vital role in regulating T cells and which was discovered by our Chief Scientific Officer and Chief Medical Officer Dr. Frederic Triebel.

Our objective is to harness and strengthen the power of patients’ immune systems through therapeutic intervention for the benefit of patients’ health. We have one pre-clinical and three clinical LAG-3 product candidates under development, including two antibodies for modulating immune responses in autoimmunity and cancer, through pharmaceutical partnerships, with Novartis and GlaxoSmithKline.

Our lead product candidate is eftilagimod alpha (LAG-3Ig or IMP321), a first-in-class antigen presenting cell (APC) activator currently being investigated in clinical trials as a treatment (in combination with chemotherapy or immune therapy) for breast cancer and melanoma.

Latest Media Releases

Immutep Quarterly Activities Report and Appendix 4C

29/10/2024 10:02:00

Key points: Positive feedback received from US FDA regarding the planned TACTI-004 Phase III in first-line non-small cell lung cancer successfully concluding regulatory preparations for the …

Immutep - Annual report to shareholders

22/10/2024 13:10:00

On behalf of the Board, I’m pleased to present Immutep Limited’s Annual Report for the 2024 Financial Year. Immutep continues to be the leading biotech focused on the development of p…

Latest News